Neuronetics, Inc.

DB:NRC Stock Report

Market Cap: €113.6m

Neuronetics Valuation

Is NRC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NRC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate NRC's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate NRC's future cash flow value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NRC?

Key metric: As NRC is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for NRC. This is calculated by dividing NRC's market cap by their current revenue.
What is NRC's PS Ratio?
PS Ratio0.8x
SalesUS$151.64m
Market CapUS$130.13m

Price to Sales Ratio vs Peers

How does NRC's PS Ratio compare to its peers?

The above table shows the PS ratio for NRC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.4x
R0Z Redsense Medical
2.2xn/a€65.6m
SBS Stratec
1x7.13%€249.2m
NN6 NanoRepro
4.7x42.17%€24.6m
AAQ1 aap Implantate
1.7xn/a€21.8m
NRC Neuronetics
0.8x9.16%€130.1m

Price-To-Sales vs Peers: NRC is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (2.4x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does NRC's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
PHH2 Paul Hartmann
0.3xn/aUS$813.41m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
K1Z0 Chordate Medical Holding
0.02xn/aUS$2.54k
No more companies available in this PS range
NRC 0.8xIndustry Avg. 2.9xNo. of Companies4PS0246810+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: NRC is good value based on its Price-To-Sales Ratio (0.8x) compared to the European Medical Equipment industry average (2.9x).

Price to Sales Ratio vs Fair Ratio

What is NRC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NRC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.8x
Fair PS Ratio1x

Price-To-Sales vs Fair Ratio: NRC is good value based on its Price-To-Sales Ratio (0.8x) compared to the estimated Fair Price-To-Sales Ratio (1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NRC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€1.57
€3.94
+151.05%
36.85%€6.13€2.63n/a4
Jul ’27€1.11
€3.69
+232.46%
43.51%€5.96€2.55n/a3
Jun ’27€1.03
€3.69
+260.03%
43.51%€5.96€2.55n/a3
May ’27€1.41
€3.74
+165.92%
43.51%€6.04€2.59n/a3
Apr ’27€1.29
€3.78
+193.34%
43.51%€6.10€2.62n/a3
Mar ’27€1.18
€5.47
+365.45%
10.88%€5.89€4.63n/a3
Feb ’27€1.72
€5.54
+222.24%
10.88%€5.96€4.68n/a3
Jan ’27€1.14
€5.54
+386.47%
10.88%€5.96€4.68n/a3
Dec ’26€1.25
€5.61
+348.71%
10.88%€6.04€4.75n/a3
Nov ’26€2.31
€5.58
+141.90%
10.88%€6.00€4.72n/a3
Oct ’26€2.24
€5.58
+148.92%
10.88%€6.00€4.72n/a3
Sep ’26€2.76
€5.58
+102.02%
10.88%€6.00€4.72n/a3
Aug ’26€3.62
€5.89
+62.94%
15.04%€6.90€4.74n/a3
Jul ’26€2.84
€6.04
+112.70%
15.04%€7.07€4.86€1.113
Jun ’26€3.32
€6.04
+81.95%
15.04%€7.07€4.86€1.033
May ’26€3.68
€6.31
+71.54%
15.04%€7.39€5.08€1.413
Apr ’26€3.35
€6.31
+88.72%
15.04%€7.39€5.08€1.293
Mar ’26€3.82
€3.24
-15.24%
37.42%€4.86€1.94€1.183
Feb ’26€3.23
€2.54
-21.47%
17.68%€2.85€1.90€1.723
Jan ’26€1.38
€2.54
+83.81%
17.68%€2.85€1.90€1.143
Dec ’25€0.87
€2.54
+190.22%
17.68%€2.85€1.90€1.253
Nov ’25€0.93
€3.03
+225.38%
14.14%€3.63€2.72€2.313
Oct ’25€0.66
€3.03
+356.41%
14.14%€3.63€2.72€2.243
Sep ’25€0.75
€3.03
+303.47%
14.14%€3.63€2.72€2.763
Aug ’25€1.68
€6.51
+286.91%
11.66%€7.44€5.58€3.623
Jul ’25€1.62
€6.51
+300.73%
11.66%€7.44€5.58€2.843
€3.88
Fair Value
59.6% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/29 19:24
End of Day Share Price 2026/07/29 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Neuronetics, Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sam EiberBTIG
William PlovanicCanaccord Genuity
Daniel StauderCitizens JMP Securities, LLC